Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First in human clinical study of OraPro-COVID-19

Trial Profile

A First in human clinical study of OraPro-COVID-19

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 24 Mar 2020

At a glance

  • Drugs COVID-19 vaccine Stabilitech Biopharma (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 24 Mar 2020 New trial record
    • 19 Mar 2020 According to a Stabilitech Biopharma media release, the company plans to initiate this study within weeks.

Trial Overview

Purpose

This trial will evaluate OraPro-COVID-19.

Diseases Treated

Indication Qualifiers Patient Segments
COVID 2019 infections treatment -

Subjects

  • Subject Type patients
  • Sex male & female

Trial Details

Organisations

  • Affiliations Stabilitech Biopharma

Trial Dates

Other Details

  • Design prospective
  • Phase of Trial Phase I
  • Location Unknown
  • Focus Adverse reactions; First in man

Interventions

Drugs Route Formulation
COVID-19 vaccine Stabilitech BiopharmaPrimary Drug Oral
-

OraPro-COVID-19

Trial History

Event Date Event Type Comment
24 Mar 2020 New trial record New trial record Updated 24 Mar 2020
19 Mar 2020 Other trial event According to a Stabilitech Biopharma media release, the company plans to initiate this study within weeks. Updated 24 Mar 2020

References

  1. Stabilitech Biopharma. Stabilitech's COVID-19 Vaccine Intended to Be Delivered in a Disruptive Thermally Stable Oral Capsule. Media-Rel 2020;.

    Media Release
Back to top